• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Highlights of India’s first Biotech startup Expo
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid
  • Moderna and Pfizer: Lawsuits and Charitable Giving
  • European Commission Approves Two GM Crops for Food and Feed
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»SARS- CoV2 & COVID-19 Updates»Points to consider before Pfizer vaccine approval in India

Points to consider before Pfizer vaccine approval in India

0
By Biotech Express on May 27, 2021 SARS- CoV2 & COVID-19 Updates

US pharmaceutical company Pfizer has sought fast-track approval for its vaccine in India. It is in talks with the Centre to roll out 5 crore doses between July and October this year, while asking for significant regulatory relaxations, according to PTI. It has told the government that the vaccine was suitable for everyone aged 12 years or older, and more importantly, can be safely stored for a month at 2 to 8 degrees Celsius.

Pfizer has told the government its COVID vaccine shows “high effectiveness” against the India-dominant variant of the virus.  It is ready to roll out five crore doses between July and October – ‘ONLY’ if it receives significant regulatory relaxations, including indemnification, or protection from compensation claims in case of adverse events. None of the three vaccines currently approved for use in India – Covishield, Covaxin or Sputnik V – have been given such protection. Pfizer has insisted on this, which it has been given by other countries that use the drug, including the United States and several European nations.

The government said last month it would fast-track approval for some foreign shots, with companies now required to do a local trial within 30 days of approval, not before. Russia’s Sputnik V is the third vaccine to receive emergency-use authorization in India after the Serum Institute’s Covishield and Bharat Biotech’s Covaxin.

Pfizer (and Moderna, another US pharma giant with a Covid vaccine) was last week approached by the Delhi government, which was looking to buy vaccines directly from them. The offer was rejected; Pfizer cited company policy to say it would only deal with the centre.

Let us see why Pfizer is not a candidate to buy in:

Regulatory approvals – Pfizer has been criticized earlier for approvals in other countries. Dr. Anthony Fauci in December 2020 said the UK approved Pfizer’s COVID-19 vaccine too fast when UK became the first Western nation to authorize a COVID-19 shot. He added that, UK regulators hadn’t scrutinized the Pfizer trial data as “carefully” as the US Food and Drug Administration, and he warned that rapid approvals could reduce public confidence in the shot. The vaccine hesitancy has become a common phenomenon due to lack of trust in companies and regulators.

Safety and Efficacy – Though the Pfizer vaccine has been approved in several countries, reporting of each and every case is not been made possible. Lifelong complications have been seen after Pfizer dose in US alone.

Side effects– Pfizer is an mRNA vaccine and such vaccines have shown serious side effects like anaphylaxis and blood clots (Astrazeneca). Out of total vaccination in 1,893,360 individuals, 4,400 adverse events were reported  in USA, 21 cases determined to be anaphylaxis, according to a report by the Centers for Disease Control and Prevention (CDC) January 07, 2021.

Price – The price of Pfizer in US is around $20 or Rs. 1500 in Indian currency which is much higher than the price offered by Indian vaccines makers at Just around $3-6.

Population – The U.S. population today, at the start of 2020, numbers just over 331 million people third largest after China and India, at around 1.4 billion. Both the prices and efficacy studies scenarios are completely different in Indian scenario. Also given the Indian population, it has huge market for any vaccine manufacturer.

Vaccine politics and Nationalism – Every nation has praised their vaccine and showed diplomacy over treatment. After a huge funding and research Indian firm Bharat Biotech has bring out a vaccine that is both cost effective and safe over to other vaccines. But comparing the regulatory approvals in agencies raises serious doubts on the working of these agencies when they quickly approve US made Pfizer but not India made covaxin.

Foreign Exchange – Approval of a foreign vaccine despite having effective indigenous vaccine can cause huge money going outside India as foreign exchange which is not synonymous with India’s growth dream.

Variants – Pfizer has shown that it works against Indian variants but the study need more bridging studies to establish the fact, whereas Indian vaccines have shown good effectiveness and less side effects in Indian population when they already have administered 20 crore doses.

Safe play –Last and most important, Pfizer has sought for indemnity which is a very crucial point to consider in cases of side effects as already people have become hesitant to vaccine and further ignorance of vaccine companies toward causalities can completely erode trust in Indian vaccines too.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Researchers who jumped into the field from distant disciplines published lower impact work, study finds

Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid

No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible?

Leave A Reply Cancel Reply

Current Issue – May 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
  • Moderna and Pfizer: Lawsuits and Charitable Giving May 25, 2022
  • European Commission Approves Two GM Crops for Food and Feed May 25, 2022
  • Ayush Ministry, DBT sign MoU for cooperation on evidence-based biotech interventions in Ayush sector May 24, 2022
  • CCI, India merger approved absorption of Covidshield Technologies into Biocon Biologics May 20, 2022
  • No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible? May 19, 2022
  • Industry lobbying on WHO overshadowing public health policy, researchers suggest May 18, 2022
  • Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha May 15, 2022
  • Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande May 15, 2022
  • Bill Gates tests positive for COVID-19 even after many booster doses, mocked on twitter May 10, 2022
  • Another Ivermectin COVID-19 paper retracted May 8, 2022
  • COVID-19 spike protein paper retracted May 7, 2022
  • Killer Music? Can sound make a clot in a boy who died while dancing or it is related to COVID vaccination May 7, 2022
  • Clotting Risks Cause FDA to Restrict Use of J&J COVID Vaccine May 6, 2022
  • Department of Pharmaceuticals releases “Common Guidelines on Pharmaceutical Innovation and Entrepreneurship” for academic institutions May 6, 2022
  • No medical care for 45% of recorded deaths in 2020, highest ever in India: New data May 6, 2022
  • Indian opposition seeks higher compensation for COVID deaths after damning WHO report May 6, 2022
  • Redcliffe Lifetech raises $61 million in Series B funding May 6, 2022
  • Engineers Create an Enzyme That Breaks Down Plastic Waste in Hours, Not Decades May 5, 2022
  • Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr May 5, 2022
  • The Union Government has Lied to the Supreme Court in COVID Vaccines Case? May 5, 2022
  • COVID-19- vitamin D paper from India retracted by Springer Nature journal May 4, 2022
  • IISc develops 3D printed gloves for rehabilitating stroke patients May 4, 2022
  • A new wearable technology — for plants May 4, 2022
  • Sanofi India names Rodolfo Hrosz managing director effective June 1 May 4, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.